StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for PTN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $14.91 | $15.24 | +2.21% | 0.0M |
| 05-19 | $14.72 | $14.27 | -3.06% | 0.0M |
| 05-20 | $14.27 | $14.59 | +2.24% | 0.0M |
| 05-21 | $14.56 | $14.43 | -0.89% | 0.0M |
| 05-22 | $14.80 | $14.88 | +0.52% | 0.0M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical needs and commercial potential. The Company's business is in one operating segment: life science.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 |
|---|---|---|
Revenue | $12.88M | $8.96M |
Operating Income | $-4.25M | $-2.67M |
Net Income | $-4.02M | $-2.59M |
EPS (Diluted) | $-1.63 | $-1.47 |
Total Assets | $13.23M | $17.93M |
Total Liabilities | $2.63M | $6.46M |
Cash & Equivalents | $10.16M | $14.48M |
Free Cash Flow OCF − CapEx | $-10.89M | $-6.44M |
Shares Outstanding | 1.78M | 1.76M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.